Plant Name: Inula helenium
Taxonomic Information:
Plant ID: NPO17755
Plant Latin Name: Inula helenium
Taxonomy Genus: Inula
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
55635
Plant-of-the-World-Online:
225914-1
Used in Medicines:
Country/Region:
Albania; Italy; Lithuania; Finland; India; China; Iraq; BulgariaTraditional Medicine System:
Unani; TCM; Homeopathy; AyurvedaGeographical Distribution:
Canada; Turkey; Italy; Turkmenistan; Lithuania; Mongolia; France; Netherlands; Ireland; Norway; Uzbekistan; Belarus; Iran; Iceland; China; Germany; Iraq; Kazakhstan; Poland; Spain; Ukraine; Georgia; Denmark; Philippines; Indonesia; United States; Sweden; Finland; New Zealand; Russia; Bulgaria; Romania; Albania; Portugal; South Africa; India; United Kingdom; Austria; Greece; Hungary; Tajikistan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| TSHR; | |
| MAPK1; | |
| PPARA; | |
| ALOX15; HSD17B10; | |
| MMP2; MMP9; MMP1; | |
| NFKB1; | |
| FABP3; FABP4; LMNA; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 4.088E-09 | 6.791E-05 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.625E-07 | 2.087E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0071248; cellular response to metal ion | 4.230E-06 | 6.579E-03 | ALOX15, FABP4, MAPK1, MMP9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.233E-09 | 1.479E-07 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.041E-08 | 1.224E-06 | MMP1, MMP2, MAPK1, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.659E-06 | 3.064E-04 | MMP1, MMP2, MAPK1, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.191E-05 | 3.574E-04 | MAPK1, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 5.442E-05 | 1.088E-03 | MMP2, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.127E-05 | 1.088E-03 | MMP2, MAPK1, MMP9 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 7.019E-05 | 1.203E-03 | MAPK1, MMP9, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.436E-04 | 1.915E-03 | LMNA, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.234E-04 | 1.851E-03 | MAPK1, PPARA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.626E-04 | 1.951E-03 | MAPK1, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.284E-04 | 4.674E-03 | MMP2, MAPK1, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 7.898E-04 | 7.013E-03 | FABP4, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 8.182E-04 | 7.013E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.292E-03 | 7.298E-03 | MAPK1, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.095E-03 | 7.298E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 8.182E-04 | 7.013E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.302E-03 | 7.298E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.338E-03 | 7.298E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 1.231E-03 | 7.298E-03 | PPARA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 1.063E-03 | 7.298E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.338E-03 | 7.298E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.338E-03 | 7.298E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.980E-03 | 9.504E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 2.069E-03 | 9.548E-03 | MMP2, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.412E-03 | 7.365E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 1.850E-03 | 9.252E-03 | MAPK1, NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; MMP9; MAPK1; MMP2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MAPK1; MMP2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
